BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29847177)

  • 1. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.
    Niu S; Bremner DH; Wu J; Wu J; Wang H; Li H; Qian Q; Zheng H; Zhu L
    Drug Deliv; 2018 Nov; 25(1):1275-1288. PubMed ID: 29847177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
    Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
    Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
    Ma Y; Li R; Dong Y; You C; Huang S; Li X; Wang F; Zhang Y
    Int J Nanomedicine; 2021; 16():789-802. PubMed ID: 33568906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
    Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
    J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
    Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
    Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
    [No Abstract]   [Full Text] [Related]  

  • 6. Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer.
    Sharma R; Yadav V; Jha S; Dighe S; Jain S
    Carbohydr Polym; 2024 Aug; 338():122196. PubMed ID: 38763723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy.
    Zhang X; Niu S; Williams GR; Wu J; Chen X; Zheng H; Zhu LM
    Carbohydr Polym; 2019 Oct; 221():84-93. PubMed ID: 31227170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
    Wang W; Xi M; Duan X; Wang Y; Kong F
    Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
    Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ
    Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
    Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
    Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
    Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
    Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Meléndez-Alafort L; Trujillo-Nolasco M; Ocampo-García B
    Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110043. PubMed ID: 31546458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
    Duan XC; Yao X; Zhang S; Xu MQ; Hao YL; Li ZT; Zheng XC; Liu M; Li ZY; Li H; Wang JR; Feng ZH; Zhang X
    Int J Nanomedicine; 2019; 14():195-204. PubMed ID: 30636872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
    Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
    Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
    Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
    Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.
    Di Mauro PP; Cascante A; Brugada Vilà P; Gómez-Vallejo V; Llop J; Borrós S
    Int J Pharm; 2018 Dec; 553(1-2):169-185. PubMed ID: 30321641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel brain-targeted nanomicelles for anti-glioma therapy mediated by the ApoE-enriched protein corona in vivo.
    Zhang ZA; Xin X; Liu C; Liu YH; Duan HX; Qi LL; Zhang YY; Zhao HM; Chen LQ; Jin MJ; Gao ZG; Huang W
    J Nanobiotechnology; 2021 Dec; 19(1):453. PubMed ID: 34963449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.